TY  - JOUR
T1  - ß-adrenergic blocking agents in the post-myocardial infarction patient
AU  - Goldstein S
Y1  - 1979/10/01
N1  - 10.1001/archinte.1979.03630470011004
JO  - Archives of Internal Medicine
SP  - 1089
EP  - 1090
VL  - 139
IS  - 10
N2  - The β-adrenergic agent, propranolol hydrochloride, has become an important adjunct to the treatment of patients with coronary artery disease. Propranolol has become the foundation for the current medical treatment of angina pectoris based primarily upon the impressive symptom relief experienced following its administration. It is, however, unfortunate that there are little data relating to propranolol's effect on long-term morbidity and mortality in angina pectoris. As an extension of its presumed effectiveness in angina pectoris, propranolol is now being used in the routine treatment of patients who have experienced an acute myocardial infarction, regardless of the clinical course or symptom status. This therapy philosophy has been based largely on a number of studies performed in Europe using, for the most part, β-adrenergic blocking agents other than propranolol. Although these reports suggest that β-adrenergic blocking agents may improve survival following an acute myocardial infarction, it is far from a proven fact that
SN  - 0003-9926
M3  - doi: 10.1001/archinte.1979.03630470011004
UR  - http://dx.doi.org/10.1001/archinte.1979.03630470011004
ER  -